Genome Publications
https://doi.org/10.61096/978-81-994851-8-1_4

Chapter 4

Advancements in Role of Artificial Intelligence in Liquid Crystal Formulation in Different Drug Delivery Systems

G. Lavanya[1], M. Keerthana[1], A. Anusha[1], K. Saisruthi[1]
[1]Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visva Vidyalayam, Tirupati, A.P. -517502

1. Abstract: Artificial Intelligence (AI) has rapidly evolved into a transformative technology capable of performing complex cognitive tasks, accelerating scientific research, and enabling unprecedented precision in pharmaceutical formulation. In recent years, AI-driven computational tools and machine learning algorithms have significantly impacted the development of liquid crystalline (LC) drug delivery systems Artificial Intelligence (AI), particularly through the integration of machine learning (ML) techniques, has emerged as a transformative force capable of accelerating scientific innovation and addressing complex challenges in pharmaceutical formulation (1). advanced nanostructured platforms known for their ability to improve drug solubility, enhance stability, and provide sustained or controlled drug release. (2) Traditional LC formulation requires extensive experimental screening to identify optimal excipient ratios and stable mesophases; however, AI now enables rapid virtual prediction of LC phase behaviour, drug–excipient compatibility, and formulation stability by analysing large datasets of physicochemical and structural parameters. These capabilities reduce development timelines, minimize material consumption, and enhance formulation accuracy. (3) Moreover, AI-based modelling facilitates optimization of lipid–surfactant–water compositions, predicts rheological and release characteristics, and supports automated interpretation of advanced characterization techniques such as SAXS/WAXS, TEM, and FESEM. By integrating patient-specific clinical data, AI further enables the customization of LC-based drug delivery systems for personalized therapy, improving therapeutic efficacy and patient outcomes. (4,5) This review provides a comprehensive overview of AI applications in LC formulation across various drug delivery systems, including oral, transdermal, ophthalmic, pulmonary, and injectable platforms. The benefits, challenges, and future potential of AI-guided LC development are discussed, emphasizing the role of intelligent technologies in revolutionizing modern pharmaceutical design and ensuring more efficient, cost-effective, and clinically impactful drug delivery solutions. (6,7,8)

Keywords: AI, ML, Liquid Crystalline Drug Delivery Systems, Pharmaceutical Formulation, Controlled Drug Release, Personalized Medicine.

Citation: G. Lavanya, M. Keerthana, A. Anusha, K. Saisruthi. Advancements in Role of Artificial Intelligence in Liquid Crystal Formulation in Different Drug Delivery Systems. Integrating Artificial Intelligence in Pharmacy: Execution and Exploration. 2025; Pp32-48.
https://doi.org/10.61096/978-81-994851-8-1_4

2. Introduction

Definition of Liquid Crystals

Liquid crystals are states of matter that combine properties of both liquids and solids. They flow like liquids but retain a certain level of molecular ordering similar to crystals. Because of this unique combination, liquid crystals can form structured phases such as nematic, smectic, cubic, and hexagonal which make them highly suitable for controlled and targeted drug delivery applications.

Definition of Artificial Intelligence in Drug Delivery

Artificial intelligence (AI) in drug delivery refers to the use of advanced computational algorithms and machine-learning models to design, optimize, and predict the behavior of drug formulations. AI analyses large datasets to identify the best excipients, forecast release profiles, optimize dosage forms, and personalize treatment strategies. By reducing trial-and-error experiments and improving accuracy, AI accelerates the development of safer, more effective, and patient-specific drug delivery systems.

The pharmaceutical sciences are undergoing a profound transformation driven by the convergence of computational technologies, data-intensive methodologies, and next–generation material-based drug delivery platforms. Among these technologies, Artificial Intelligence (AI) encompassing machine learning (ML), deep learning (DL), and predictive analytics has become a central engine for innovation. With the exponential rise of digital data in pharmaceutical research, AI algorithms now enable high-throughput pattern identification, prediction of complex physicochemical behaviors, and automation of formulation processes. These capabilities directly address long-standing challenges such as extended development timeframes, high costs associated with iterative experimentation, and low success rates during the transition from laboratory to clinic [1–3]. Parallel to AI advancements, liquid crystalline (LC) drug delivery systems have gained prominence due to their unique structural characteristics. LC systems form self-assembled supramolecular architectures that exhibit intermediate properties between crystalline solids and isotropic liquids. Their mesophases lamellar (Lα), BI continuous cubic (QII), and hexagonal (HII) are formed through the spontaneous organization of amphiphilic lipids in the presence of water. These nanostructures have distinct thermodynamic and rheological properties that facilitate superior drug solubilization, tunable release kinetics, high structural stability, and the ability to encapsulate hydrophilic, hydrophobic, and amphiphilic therapeutics simultaneously [4–6].

Despite their potential, LC formulations are highly sensitive systems in which multiple variables including lipid molecular geometry, critical packing parameter (CPP), hydration level, ionic strength, surfactant type, pH, and drug-to-lipid ratio govern mesophase formation. Small perturbations in these parameters can trigger transitions between mesophases (e.g., cubic → hexagonal, lamellar → cubic), making rational formulation design difficult. Conventional formulation strategies rely on empirical screening and iterative phase mapping, which require extensive experimentation, large quantities of materials, and specialized analytical expertise. This challenge positions LC technology as an ideal candidate for AI-assisted optimization.

AI and ML provide a paradigm shift by enabling predictive modelling of LC phase behavior based on physicochemical descriptors. These algorithms can identify hidden correlations between formulation parameters and resulting mesophase characteristics, which cannot be easily captured using traditional statistical tools. For example, ML models can be trained with datasets consisting of lipid tail length, headgroup charge, hydrophilic–lipophilic balance (HLB), water activity, drug logP, Hansen solubility parameters, and rheological indices to forecast LC structure and stability with high accuracy [7–9]. Techniques such as artificial neural networks (ANNs), support vector machines (SVMs), gradient boosting algorithms, and random forest models are increasingly used to predict mesophase transitions, optimize component ratios, and estimate mechanical properties like viscosity and elasticity.

In LC characterization, AI enhances the interpretation of complex analytical outputs. Structural characterization of LC phases typically involves advanced techniques such as Small-Angle X-ray Scattering (SAXS) for lattice symmetry analysis, Transmission Electron Microscopy (TEM) for direct visualization of nanostructures, and Polarized Optical Microscopy (POM) for birefringence pattern recognition. These datasets often exhibit high dimensionality and variability. AI-driven image analysis, powered by convolutional neural networks (CNNs), can automatically classify mesophases, quantify domain sizes, detect defects in nano structural ordering, and differentiate between similar diffraction profiles significantly improving precision and reducing human subjectivity [10–12].

Another frontier where AI intersects with LC technology is personalized drug delivery. Incorporating patient-level data such as metabolic phenotype, disease biomarkers, mucosal permeability, and enzyme expression allows AI to tailor LC formulations to individual therapeutic requirements. Such personalization may include adjusting drug loading, selecting an appropriate mesophase for targeted release, or modifying rheology for site-specific administration. These strategies align with the shift toward precision medicine and individualized treatment pathways [13,14]. Despite the promising integration of AI into LC formulation science, certain limitations persist. AI models require large, high-quality datasets for accurate training; however, LC research often suffers from small sample sizes and insufficient standardization across laboratories. Model interpretability remains a challenge, especially when using deep learning approaches where decision-making occurs in opaque layers. Further, regulatory agencies are still developing frameworks to evaluate and approve AI-driven formulation decisions, raising concerns about reproducibility, transparency, and algorithmic bias. Nevertheless, ongoing advancements in computational modeling, big-data infrastructure, automation, and laboratory robotics suggest that AI-assisted LC formulation will become a cornerstone of next-generation pharmaceutical technology. By integrating predictive tools with advanced material systems like liquid crystals, the pharmaceutical industry can accelerate the development of smarter, more efficient, and patient-specific drug delivery solutions.

Enhancements of liquid crystals in AI drug delivery system

Artificial intelligence (AI) greatly enhances drug delivery by accelerating formulation development, improving prediction of drug release, and optimizing dosage forms with high precision. By analysing large and complex datasets, AI can identify ideal excipient combinations, forecast stability under various conditions, and

significantly reduce trial-and-error experimentation. AI-driven modeling also supports personalized medicine by tailoring drug dosing and delivery strategies to individual patient characteristics, such as metabolic rate, genetics, and disease progression. In addition, AI improves safety by predicting toxicity risks early, detecting potential formulation failures, and guiding researchers toward safer alternatives. It further strengthens decision-making by integrating data from advanced characterization techniques, in silico simulations, and clinical outcomes. Overall, AI transforms drug delivery into a faster, smarter, and more reliable process, enabling the development of highly efficient and patient-centric therapeutic systems.



Figure 1. *Schematic representation of the advancements in the role of artificial intelligence (AI) in liquid crystal (LC) formulation for different drug delivery systems.* The figure illustrates how AI supports LC-based pharmaceutical development across multiple domains, including prediction of phase behavior, reduction of experimental workload, personalization of drug delivery, optimization of material selection, and automation of characterization processes. The interconnected blocks emphasize AI-driven improvements in efficiency, accuracy, and decision-making throughout formulation and evaluation stages.

3. Current Pharmaceutical Challenges and the Role of Artificial Intelligence

The pharmaceutical sector continues to encounter a wide range of scientific and operational challenges as it strives to develop effective and economically viable therapeutics. Although small-molecule drugs remain central to drug discovery due to their synthetic versatility, cost-effectiveness, and generally predictable chemical behavior, their development landscape is becoming increasingly competitive. Many new chemical entities must compete directly with generic alternatives, and their successful

launch requires extensive preclinical and clinical evaluation, adding significant financial burden to companies. Despite their advantages, small molecules often suffer from issues related to limited stability, structural modifications, and therapeutic specificity, which hinder innovation in this area [20–26].

In contrast, biomolecular therapeutics including peptides, proteins, and nucleic acid-based constructs have demonstrated remarkable clinical success, as seen with widely used medicines such as insulin and monoclonal antibodies like adalimumab. However, these large molecules bring unique challenges of their own. Their structural integrity, biological activity, and pharmacokinetic profiles are dictated by their amino acid sequences, nucleic acid architecture, and three-dimensional conformation. Most biologics require parenteral administration via infusion or injection, and their pharmacokinetic optimization, stabilization, and delivery remain key research priorities in modern pharmaceutical science [27–33].

To navigate these increasing complexities, advanced technological tools such as artificial intelligence (AI) have gained substantial importance. AI supports drug discovery and development by analysing large datasets, predicting molecular interactions, optimizing experimental conditions, and identifying promising therapeutic candidates. However, despite its powerful capabilities, AI does not fully replace human expertise. Many AI-driven predictions rely heavily on the quality and diversity of training datasets, leaving room for algorithmic bias, inaccurate pattern recognition, or misinterpretation of computational outputs. Cases such as docking simulations identifying false-positive drug candidates highlight the need for expert oversight. Thus, while AI accelerates data processing and hypothesis generation, final decisions still require human interpretation to ensure scientific accuracy and to eliminate potential systematic errors [33,].

AI methodology in pharmaceutical applications commonly involves machine learning approaches and their subsets, such as deep learning (DL) and natural language processing (NLP). Depending on the task, algorithms may function through supervised learning, where models are trained on labelled datasets to predict known outcomes, or unsupervised learning, where hidden patterns and clusters are identified without predefined labels. Supervised learning is particularly suited for classification and regression tasks, such as predicting drug solubility or biological activity, while unsupervised learning excels in discovering relationships within complex datasets, such as grouping molecular structures or analysing clinical trial patterns.

A wide range of machine learning architectures are now applied in pharmaceutical development including decision trees, random forests, support vector machines, convolutional neural networks, natural language understanding models, and reinforcement learning frameworks. These computational models are increasingly used to support formulation decisions, molecule design, optimization of manufacturing parameters, prediction of drug–target interactions, and modeling of patient-specific therapeutic responses. Representative AI models commonly utilized across pharmaceutical research and development.



Figure 2. Integrative AI Framework for Material Selection, Characterization, and Design of LC Drug Delivery Systems



Figure X. Overview of supervised and unsupervised learning techniques used in pharmaceutical and drug-formulation research.

Table 1. Top 10 Commonly Used AI/Machine Learning Models in the Pharmaceutical Industry (1,2)

AI / ML Model	Description / Usage
Generative Adversarial Networks (GANs)	Used to create new drug-like molecules. A generator proposes chemical structures while a discriminator checks their quality, resulting in diverse and optimized molecular candidates.
Recurrent Neural Networks (RNNs)	Applied to sequence-related tasks such as protein prediction, genomic analysis, and peptide design. They learn patterns from ordered biological sequences.
Convolutional Neural Networks (CNNs)	Useful for image-based analysis like studying molecular images and identifying drug targets. They extract visual features important for drug design.
Long Short-Term Memory Networks (LSTMs)	Handle long-term temporal data; applied in pharmacokinetic/pharmacodynamic modeling to predict drug concentration–time profiles.
Transformer Models (e.g., BERT)	Used for natural language processing in pharma. Extract insights from scientific papers, patents, and clinical trial reports to support research decisions.
Reinforcement Learning (RL)	Helps optimize drug dosing and design personalized treatment strategies by learning from repeated interactions with the environment.
Bayesian Models	Enable uncertainty estimation and probabilistic decision-making. Used for risk assessment, prediction, and optimization of experimental designs.
Deep Q-Networks (DQNs)	Combine deep learning with reinforcement learning to evaluate compound activity and identify promising drug candidates in discovery pipelines.
Autoencoders	Perform dimensionality reduction and extract hidden features of molecules. Support virtual screening and compound characterization.
Graph Neural Networks (GNNs)	Designed for molecular graph data. Predict molecular properties, model chemical interactions, and support de novo drug design.

4. Structure of liquid crystal:



Fig 3: Structure of liquid crystals

4.1 Types of liquid crystal



Fig 4. Types of liquid crystals

4.2 Effective Preparation Method of Liquid Crystalline Systems [7,8]

The emulsion-based method is an effective approach for preparing liquid crystalline (LC) systems by first forming a precursor emulsion and then inducing its transformation into a specific mesophase. In this technique, a conventional oil-in-water (O/W) emulsion is prepared using a lipid phase typically monoolein, phytantriol, or other amphiphilic lipids dispersed within an aqueous phase containing suitable stabilizers or surfactants. Once the emulsion is formed, structural reorganization is triggered by adjusting key parameters such as hydration level, temperature, or solvent polarity. As water penetrates and hydrates the lipid domains, the internal lipid arrangement undergoes a thermodynamically driven transition, resulting in the formation of ordered mesophases such as cubic (QII), hexagonal (HII), or lamellar (Lα) structures. This method is advantageous because it allows controlled formation of LC nanoparticles and supports the encapsulation of both hydrophilic and hydrophobic drugs within different regions of the self-assembled matrix. However, the technique requires precise control over hydration kinetics, surfactant concentration, and temperature to ensure reproducible mesophase formation. If these parameters are not carefully optimized, the resulting formulations may exhibit instability or incomplete phase transition, affecting drug loading, release behavior, and structural integrity.

4.3 Optimization of liquid crystals



5. AI-Based Characterization of Liquid Crystals [7-10]

A. AI-Assisted SAXS/WAXS Characterization

Small-angle and wide-angle X-ray scattering (SAXS/WAXS) are fundamental tools for determining the internal nanostructure of liquid crystalline (LC) systems, as they provide detailed information on lattice dimensions, peak spacing, and mesophase identity. Traditionally, interpreting these diffraction patterns requires highly skilled analysts because the peaks can overlap, vary in intensity, or become distorted when drugs or excipients are incorporated. Artificial intelligence has greatly enhanced this process by enabling automated peak detection, classification, and lattice parameter calculation. Machine learning models particularly convolutional neural networks are trained on extensive datasets of scattering patterns and can rapidly identify cubic, hexagonal, or lamellar phases with superior accuracy. AI not only reduces human error but also accelerates the analysis workflow dramatically, transforming what could take hours of manual interpretation into a task completed in minutes. This improvement

allows researchers to process large numbers of samples efficiently and ensures consistent mesophase identification across different labs and experiments.



Fig 5. AI-Assisted SAXS/WAXS of liquid crystals

B.AI-Enhanced Interpretation of TEM and Cryo-TEM Images

Transmission electron microscopy (TEM) and cryogenic TEM (cryo-TEM) offer high-resolution visualization of LC nanostructures such as cubosomes, hexosomes, and lamellar sheets. Although these techniques provide invaluable structural insight, manual interpretation of micrographs is often time-consuming and subjective, and requires expert knowledge of electron density patterns and structural signatures. AI-based image analysis overcomes these limitations by automating key components of the interpretation process. Deep-learning algorithms can identify characteristic internal structures, classify mesophases, detect defects in the self-assembled architecture, and quantify particle morphology with exceptional precision. The use of AI allows thousands of TEM images to be analyzed in a fraction of the time required by traditional manual methods. This leads to improved reproducibility and objectivity in structural characterization and enables the discovery of nano structural features that may be challenging for the human eye to detect.



Fig 6. AI-Enhanced Interpretation of TEM and Cryo-TEM Images of liquid crystals

C. AI-Based FESEM/SEM Morphological Assessment

Field emission scanning electron microscopy (FESEM) and scanning electron microscopy (SEM) are widely used to examine the surface morphology and external particle architecture of LC nanoparticles. Conventional visual assessment often suffers from operator bias and limited reproducibility, particularly when distinguishing subtle morphological differences or identifying aggregation in complex systems. AI brings a new level of precision to these analyses by extracting quantitative features from electron micrographs using machine learning algorithms. These systems can measure particle dimensions, surface roughness, porosity, and aggregation patterns with high fidelity. AI models also correlate morphological parameters with functional characteristics such as stability and release behavior. Through automated pattern recognition, AI ensures consistent, unbiased, and high-throughput evaluation of LC nanoparticle morphology, making it an indispensable tool for formulation scientists.



Fig 7. AI-Based FESEM/SEM Morphological Assessment of liquid crystals

D. AI-Assisted Rheological Characterization

Rheology provides critical insights into the flow behavior, viscoelasticity, and structural integrity of liquid crystalline systems. These properties strongly influence the performance of LC formulations in applications such as injectables, topical systems, or in situ forming gels. AI improves rheological characterization by predicting flow curves, viscosity, storage modulus, and yield stress based on formulation composition and processing parameters. Machine learning models trained on experimental rheology data can anticipate how changes in lipid composition, water content, temperature, or drug loading will modify mechanical behavior. This predictive capacity greatly reduces dependence on repetitive physical measurements and enables researchers to fine-tune formulations for desired performance early in development. AI-driven rheological modeling thus accelerates decision-making and helps ensure consistent quality and functionality of LC systems.



Fig 8. AI-Assisted Rheological Characterization of liquid crystals

E. AI for DLS and Nanoparticle Size Distribution Analysis

Dynamic light scattering (DLS) is commonly used to measure particle size, polydispersity, and colloidal stability of LC nanoparticles. However, DLS data can be noisy or complicated by multiple scattering, especially in dense or polydisperse systems. AI enhances DLS analysis through intelligent data cleaning, signal correction, and advanced statistical modeling. Algorithms can differentiate between true particle size distributions and noise-induced artifacts, offering clearer and more reliable measurements. AI models can also predict multimodal distributions something traditional software often struggles with thus providing a more accurate representation of particle populations. This automated, highly accurate interpretation strengthens the reliability of DLS measurements and enhances the understanding of LC nanoparticle behavior in formulations.



Fig 9. AI-Assisted Rheological Characterization of liquid crystals

6. Benefits of AI-Integrated Liquid Crystal Drug Delivery Systems

Artificial intelligence (AI) is rapidly transforming pharmaceutical research by enabling faster, more accurate, and cost-effective development of drug delivery systems. When integrated with liquid crystal (LC) drug delivery platforms known for their unique mesophase structures, high drug-loading capacity, and controlled-release behavior AI provides powerful advantages. LC systems already offer tunable nano-architectures, biocompatibility, and the ability to encapsulate both hydrophilic and lipophilic drugs. By combining these features with AI-driven prediction, optimization, and automation, researchers can design smarter formulations with improved performance and reduced trial-and-error experimentation. AI-integrated LC systems thus represent a next-generation approach that enhances formulation accuracy, accelerates development timelines, and supports personalized medicine applications.



Fig 10. Benefits of AI-Integrated Liquid Crystal Drug Delivery Systems

7. AI in Liquid Crystal Systems for Different Drug Delivery Routes

Liquid crystal (LC) drug delivery systems are advanced carriers that possess organized mesophase structures, allowing them to improve drug solubility, protect sensitive molecules, and provide sustained or targeted release. Because these structures can be tuned to interact differently with the body, LC systems can be adapted for multiple delivery routes such as oral, parenteral, ocular, transdermal, and pulmonary administration.

When artificial intelligence (AI) is integrated into LC formulation development, it enhances the entire process by predicting optimal LC phases, selecting the best excipient combinations, and forecasting drug release profiles. AI also reduces trial-and-error experimentation and helps customize LC formulations for specific routes by analysing large datasets and modeling physiological conditions.

Together, AI and LC technologies create highly efficient, route-specific drug delivery systems that are more precise, stable, and patient-friendly.



Fig 11. AI in Liquid Crystal Systems for Different Drug Delivery Routes

1. Challenges and Limitations of AI in Drug Delivery

- Limited availability of high-quality, standardized datasets
- "Black-box" nature of AI reduces interpretability
- Requires skilled personnel and computational resources
- Biological variability can reduce prediction accuracy
- Data privacy, ethical concerns, and regulatory gaps
- Difficulty integrating AI models into practical lab workflows

2. Future Perspectives of AI-Driven Drug Delivery Systems

- Personalized, real-time dose adjustment using patient data
- Automation of formulation design and optimization
- Better prediction of stability, release, and performance
- Integration with digital twins and wearable technologies
- Advanced high-throughput screening driven by AI
- AI moving toward central, autonomous decision-making roles

3. Integration of AI with Emerging Pharmaceutical Technologies

- Nanotechnology: AI optimizes nanoparticle size, charge, and targeting
- 3D printing: predicts printability and personalized drug release
- Smart devices: enables sensor-driven controlled drug release
- Microfluidics: improves rapid formulation screening
- Omics + AI: better understanding of individual biological responses

4. Regulatory Considerations for AI-Based Drug Delivery Models

- Need for explainable, transparent AI models
- Requirements for high-quality, unbiased training data

- Continuous monitoring and validation of AI systems
- Strict patient-data protection and cybersecurity measures
- Standardized frameworks for documentation and risk assessment
- Regulatory alignment across global agencies (FDA, EMA, etc.)

Conclusion

Artificial intelligence has emerged as a transformative force in the development of liquid crystalline (LC) drug delivery systems, offering unprecedented precision, speed, and predictive capability across the entire formulation pipeline. By integrating machine learning, deep learning, and advanced data-analytic approaches, AI overcomes long-standing challenges associated with LC mesophase prediction, excipient screening, structural characterization, and performance optimization areas traditionally limited by labour-intensive experimentation and complex physicochemical behavior.

AI-driven tools now enable accurate forecasting of mesophase transitions, automated interpretation of SAXS, TEM, and rheological datasets, and intelligent optimization of nanoparticle size, morphology, and release profiles. These advancements significantly reduce development time, enhance reproducibility, and improve formulation accuracy. When applied to various administration routes including oral, ocular, transdermal, pulmonary, and injectable systems AI ensures route-specific tailoring of LC structures, supporting more effective and patient-friendly therapies.

Despite these advantages, challenges remain, including the need for high-quality standardized datasets, algorithm transparency, regulatory clarity, and secure handling of sensitive patient information. However, rapid progress in computational modeling, automation, digital-twin simulations, and integration with emerging technologies such as nanotechnology, microfluidics, and smart drug-delivery devices suggests a promising future.

Overall, the union of AI and LC drug delivery represents a paradigm shift toward intelligent, adaptive, and personalized pharmaceutical systems. As regulatory frameworks evolve and data-driven methodologies mature, AI-guided LC formulations are poised to become a cornerstone of next-generation drug delivery, enabling safer, more efficient, and clinically impactful therapeutic solutions.

References

1. Chan, H. P., Zeng, X., Ling, C. S., & Lim, C. S. (2021). Artificial intelligence in pharmaceutical product formulation: Current trends and future directions. *Advanced Drug Delivery Reviews*, 175, 113804.
2. Mak, K. K., & Pichika, M. R. (2019). Artificial intelligence in drug development: Present status and future prospects. *Drug Discovery Today*, 24(3), 773–780.
3. Sharma, P., Bhatia, S., Chawla, V., & Pathak, K. (2020). Liquid crystalline drug delivery systems: Innovations and development trends. *International Journal of Pharmaceutics*, 588, 119731.
4. Costa, A., Sarmento, B., & Seabra, V. (2023). Machine-learning approaches in nanomedicine and complex formulation systems. *Journal of Controlled Release*, 356, 88–105.

5. Zhang, J., & Mansour, H. M. (2021). Computational modeling and AI-based prediction of self-assembled liquid crystalline nanostructures. *Molecular Pharmaceutics*, 18(9), 3521–3535.
6. Le, T. T., Epa, V. C., Burden, F. R., & Winkler, D. A. (2012). Quantitative structure–property relationship modeling using machine learning. *Chemical Reviews*, 112(5), 2889–2919.
7. Kumar, A., & Mittal, A. (2022). Machine learning-assisted optimization of nanostructured lipid systems and lyotropic liquid crystals. *Colloids and Surfaces B: Biointerfaces*, 214, 112454.
8. Sarkar, S., & Mandal, S. (2021). Artificial intelligence-driven optimization in advanced drug delivery formulations. *Pharmaceutical Research*, 38, 1391–1406.
9. Brennan, M. C., & Bowman, M. K. (2020). AI-assisted analysis of electron microscopy images in nanomaterials research. *ACS Nano*, 14(5), 5788–5796.
10. Hoshino, T., et al. (2021). Deep-learning-based SAXS/WAXS analysis for structural determination of soft materials. *Soft Matter*, 17(12), 3260–3272.
11. Topol, E. (2019). High-performance medicine: The convergence of human and artificial intelligence. *Nature Medicine*, 25, 44–56.
12. Kumar, R., & Singh, R. (2022). AI-guided personalized nanomedicine: Future of precision drug delivery. *Advanced Drug Delivery Reviews*, 186, 114321.
13. Ullah, M., et al. (2020). Artificial intelligence in advanced drug delivery: Current landscape and future opportunities. *Journal of Drug Targeting*, 28(9–10), 963–973.
14. Patra, J. K., Das, G., et al. (2018). Nanobiotechnology in drug delivery: A review. *Journal of Nanobiotechnology*, 16, 71.
15. He, J., et al. (2021). Regulatory, ethical, and practical challenges in integrating AI into pharmaceutical development. *Nature Reviews Drug Discovery*, 20, 551–567.
16. Bender, A., & Cortés-Ciriano, I. (2021). Artificial intelligence in drug discovery: What is realistic, what are illusions? *Drug Discovery Today*, 26(2), 511–524.
17. Hughes, J. P., Rees, S., Kalindjian, S. B., & Philpott, K. L. (2011). *Principles of early drug discovery*. British Journal of Pharmacology, 162(6), 1239–1249.
18. DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). *Innovation in the pharmaceutical industry: New estimates of R&D costs*. Journal of Health Economics, 47, 20–33.
19. Mullard, A. (2017). *2016 FDA drug approvals*. Nature Reviews Drug Discovery, 16, 73–76.
20. Meanwell, N. A. (2016). *Improved physicochemical properties of small molecules in drug discovery*. Journal of Medicinal Chemistry, 59(20), 9641–9644.
21. Lipinski, C. A. (2004). *Lead- and drug-like compounds: The rule-of-five revolution*. Drug Discovery Today: Technologies, 1(4), 337–341.
22. Gleeson, M. P. (2008). *Generation of a set of simple, interpretable ADMET rules*. Journal of Medicinal Chemistry, 51(4), 817–834.
23. Waring, M. J., et al. (2015). *An analysis of the attrition of drug candidates from four major pharmaceutical companies*. Nature Reviews Drug Discovery, 14, 475–486.

24. Leader, B., Baca, Q. J., & Golan, D. E. (2008). *Protein therapeutics: A summary and pharmacological classification.* Nature Reviews Drug Discovery, 7, 21–39.
25. Walsh, G. (2018). *Biopharmaceutical benchmarks 2018.* Nature Biotechnology, 36, 1136–1145.
26. Sharma, B. (2007). *Drug delivery of proteins and peptides: Challenges and opportunities.* International Journal of Pharmaceutics, 335(1–2), 1–10.
27. Kaplon, H., Chenoweth, A., Crescioli, S., & Reichert, J. M. (2022). *Antibodies to watch in 2022.* mAbs, 14(1), 2014294.
28. Chen, X., & Liu, Y. (2023). *Advances in peptide and protein drug delivery systems.* Journal of Controlled Release, 355, 60–75.
29. Pasut, G. (2019). *PEGylation of biologics: Opportunities and challenges.* Advanced Drug Delivery Reviews, 147, 2–3.
30. Singh, R., & Singh, S. (2019). *Nucleic acid therapeutics: Challenges and opportunities.* Drug Discovery Today, 24(7), 1365–1373.
31. Jiménez-Luna, J., Grisoni, F., & Schneider, G. (2021). *Drug discovery with explainable artificial intelligence.* Nature Machine Intelligence, 2, 573–584.
32. Vamathevan, J., et al. (2019). *Applications of machine learning in drug discovery and development.* Nature Reviews Drug Discovery, 18, 463–477.
33. Liu, X., Ye, K., & van der Schaar, M. (2021). *Machine learning for drug discovery: Tasks, methods, and challenges.* IEEE Reviews in Biomedical Engineering, 14, 275–294.